研究者詳細 - 王　英正

MISC - 王　英正

分割表示 146 件中 1 - 20 件目／全件表示 >>

Long-Term Clinical Outcome After Transcoronary Cardiosphere-DerivedCell Infusion in Patients With Single Ventricle Congenital Heart Disease. 査読

平井健太, 王英正

Circulation 2023年11月

Eight-year follow-up of cardiosphere-derived cell transplantation in patients with single ventricle congenital heart disease. 査読

平井健太, 王英正

European Society of Cardiology 2023年9月

小児拡張型心筋症における心臓修復のための心臓球由来エキソソームマイクロRNA: 前臨床および安全性リードイン第1相臨床試験【JST・京大機械翻訳】|||

平井健太, 大月審一, 王英正

日本循環器学会学術集会(Web) 85th 2021年

小児循環器疾患に対する再生医療 1 Stem Cellを用いた治療

平井健太, 王英正

小児科 62 ( 6 ) 2021年

Cardiosphere-derived exosomal microRNAs for myocardial repair in pediatric dilated cardiomyopathy. 国際誌

Kenta Hirai, Daiki Ousaka, Yosuke Fukushima, Maiko Kondo, Takahiro Eitoku, Yusuke Shigemitsu, Mayuko Hara, Kenji Baba, Tatsuo Iwasaki, Shingo Kasahara, Shinichi Ohtsuki, Hidemasa Oh

Science translational medicine 12 ( 573 ) 2020年12月

記述言語：英語

Although cardiosphere-derived cells (CDCs) improve cardiac function and outcomes in patients with single ventricle physiology, little is known about their safety and therapeutic benefit in children with dilated cardiomyopathy (DCM). We aimed to determine the safety and efficacy of CDCs in a porcine model of DCM and translate the preclinical results into this patient population. A swine model of DCM using intracoronary injection of microspheres created cardiac dysfunction. Forty pigs were randomized as preclinical validation of the delivery method and CDC doses, and CDC-secreted exosome (CDCex)-mediated cardiac repair was analyzed. A phase 1 safety cohort enrolled five pediatric patients with DCM and reduced ejection fraction to receive CDC infusion. The primary endpoint was to assess safety, and the secondary outcome measure was change in cardiac function. Improved cardiac function and reduced myocardial fibrosis were noted in animals treated with CDCs compared with placebo. These functional benefits were mediated via CDCex that were highly enriched with proangiogenic and cardioprotective microRNAs (miRNAs), whereas isolated CDCex did not recapitulate these reparative effects. One-year follow-up of safety lead-in stage was completed with favorable profile and preliminary efficacy outcomes. Increased CDCex-derived miR-146a-5p expression was associated with the reduction in myocardial fibrosis via suppression of proinflammatory cytokines and transcripts. Collectively, intracoronary CDC administration is safe and improves cardiac function through CDCex in a porcine model of DCM. The safety lead-in results in patients provide a translational framework for further studies of randomized trials and CDCex-derived miRNAs as potential paracrine mediators underlying this therapeutic strategy.

DOI： 10.1126/scitranslmed.abb3336

PubMed

researchmap

Exosomes Mediate Myocardial Regeneration of Cardiac Progenitor Cells in a Swine Model of Dilated Cardiomyopathy. 査読

平井健太, 王英正

European Society of Cardiology. 2019年8月

ラットを用いた心臓内幹細胞の高濃度静脈内投与における急性期の血行動態および安全性評価

後藤拓弥, 逢坂大樹, 平井健太, 笠原真悟, 王英正

日本再生医療学会総会(Web) 18th 2019年

子ブタにおける新規フォンタン失敗モデルの生存を改善するための下大静脈バンディングの影響

王英正, 後藤拓弥, 逢坂大樹, 平井健太

日本循環器学会学術集会(Web) 83rd 2019年

エキソソームは拡張型心筋症のブタモデルにおける心臓前駆細胞の心筋再生を仲介する【JST・京大機械翻訳】|||

王英正, 平井健太, 後藤拓弥, 逢坂大樹, 大月審一

日本循環器学会学術集会(Web) 83rd 2019年

小児心臓内幹細胞における無血清培地を用いた細胞増殖および性質評価に関わる基礎的検討

逢坂大樹, 後藤拓弥, 平井健太, 笠原真悟, 王英正

日本再生医療学会総会(Web) 18th 2019年

Impact of cardiac progenitor cells on heart failure and survival in single ventricle congenital heart disease.

Sano T, Ousaka D, Goto T, Ishigami S, Hirai K, Kasahara S, Ohtsuki S, Sano S, Oh H

Circulation Research 122 ( 7 ) 994 - 1005 2018年

Impact of cardiac progenitor cells on heart failure and survival in single ventricle congenital heart disease.

Sano T, Ousaka D, Goto T, Ishigami S, Hirai K, Kasahara S, Ohtsuki S, Sano S, Oh H

Circulation Research 122 ( 7 ) 994 - 1005 2018年

記述言語：英語出版者・発行元：LIPPINCOTT WILLIAMS & WILKINS

Rationale: Intracoronary administration of cardiosphere-derived cells (CDCs) in patients with single ventricles resulted in a short-term improvement in cardiac function.Objective: To test the hypothesis that CDC infusion is associated with improved cardiac function and reduced mortality in patients with heart failure.Methods and Results: We evaluated the effectiveness of CDCs using an integrated cohort study in 101 patients with single ventricles, including 41 patients who received CDC infusion and 60 controls treated with staged palliation alone. Heart failure with preserved ejection fraction (EF) or reduced EF was stratified by the cardiac function after surgical reconstruction. The main outcome measure was to evaluate the magnitude of improvement in cardiac function and all-cause mortality at 2 years. Animal studies were conducted to clarify the underlying mechanisms of heart failure with preserved EF and heart failure with reduced EF phenotypes. At 2 years, CDC infusion increased ventricular function (stage 2: +8.410.0% versus +1.66.4%, P=0.03; stage 3: +7.9 +/- 7.5% versus -1.1 +/- 5.5%, P<0.001) compared with controls. In all available follow-up data, survival did not differ between the 2 groups (log-rank P=0.225), whereas overall patients treated by CDCs had lower incidences of late failure (P=0.022), adverse events (P=0.013), and catheter intervention (P=0.005) compared with controls. CDC infusion was associated with a lower risk of adverse events (hazard ratio, 0.411; 95% CI, 0.179-0.942; P=0.036). Notably, CDC infusion reduced mortality (P=0.038) and late complications (P<0.05) in patients with heart failure with reduced EF but not with heart failure with preserved EF. CDC-treated rats significantly reversed myocardial fibrosis with differential collagen deposition and inflammatory responses between the heart failure phenotypes.Conclusions: CDC administration in patients with single ventricles showed favorable effects on ventricular function and was associated with reduced late complications except for all-cause mortality after staged procedures. Patients with heart failure with reduced EF but not heart failure with preserved EF treated by CDCs resulted in significant improvement in clinical outcome.

DOI： 10.1161/CIRCRESAHA.117.312311.

Web of Science

researchmap

大動物フォンタン循環類似モデルと下大静脈絞扼によるプレコンディショニング戦略の検討

後藤拓弥, 逢坂大樹, 平井健太, 佐野俊和, 王英正

日本再生医療学会総会(Web) 17th 2018年

大動物フォンタン術後遠隔期モデルを目指した下大静脈絞扼術による臓器障害評価

逢坂大樹, 後藤拓弥, 佐野俊和, 平井健太, 笠原真悟, 王英正

日本再生医療学会総会(Web) 17th 2018年

新しいブタ拡張型心筋症モデルの開発と心臓内幹細胞治療の効果検証~大型動物実験からヒト第1相臨床試験へ~

平井健太, 大月審一, 馬場健児, 近藤麻衣子, 栗田佳彦, 福嶋遥佑, 重光祐輔, 原真祐子, 後藤拓弥, 逢坂大樹, 王英正

日本小児循環器学会雑誌 34 ( Supplement 1 ) 2018年

大動物フォンタン循環モデル作成に向けた下大静脈絞扼によるプレコンディショニング戦略の検証

逢坂大樹, 後藤拓弥, 佐野俊和, 平井健太, 笠原真悟, 王英正

日本循環器学会学術集会(Web) 82nd 2018年

拡張型心筋症の新規ブタモデルにおける心臓前駆細胞送達【JST・京大機械翻訳】|||

佐野俊和, 平井健太, 後藤拓弥, 逢坂大樹, 大月審一, 王英正

日本循環器学会学術集会(Web) 82nd 2018年

単心室における心臓前駆細胞適用後の臨床転帰:駆出率保持心不全の影響【JST・京大機械翻訳】|||

佐野俊和, 逢坂大樹, 平井健太, 後藤拓弥, 笠原真悟, 大月審一, 王英正

日本循環器学会学術集会(Web) 82nd 2018年

大型動物の下大静脈絞扼モデルを用いた腹部臓器うっ血による臓器障害評価

後藤拓弥, 逢坂大樹, 佐野俊和, 平井健太, 笠原真悟, 王英正

日本小児循環器学会雑誌 34 ( Supplement 1 ) 2018年

非移植群とretrospectiveに比較した機能的単心室症に対する心臓内幹細胞移植の有効性評価

佐野俊和, 逢坂大樹, 後藤拓弥, 平井健太, 石神修大, 笠原真悟, 大月審一, 佐野俊二, 王英正

日本再生医療学会総会(Web) 17th 2018年

　前のページ - 次のページ　

<王 英正>

MISC - 王 英正

<王　英正>

MISC - 王　英正